ERBB2 and breast carcinoma: The response to HER2‐targeted therapy in patients with CEP17 abnormalities is controversial,31, 32 and accurate assessment of the HER2/CEP17 signal ratio may be crucial for accurate determination of the prognosis of breast cancer patients in clinical practice.